Psychiatric and Psychological Care Utilization Among Patients with Atopic Dermatitis, Hidradenitis Suppurativa, and Psoriasis: Insights from a Propensity-Matched Real-World Cohort Analysis - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Psychiatric and Psychological Care Utilization Among Patients with Atopic Dermatitis, Hidradenitis Suppurativa, and Psoriasis: Insights from a Propensity-Matched Real-World Cohort Analysis

  • By

  • Marta Szepietowska

  • Piotr K. Krajewski

  • Przemyslaw Pacan

  • Anna Wojas-Pelc

  • Jacek C. Szepietowski

  • Andrzej K. Jaworek

  • March 3, 2026

Share

Clinical Scorecard: Psychiatric and Psychological Care Utilization Among Patients with Atopic Dermatitis, Hidradenitis Suppurativa, and Psoriasis: Insights from a Propensity-Matched Real-World Cohort Analysis

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationAdults aged 18 years and older with newly diagnosed chronic inflammatory skin disorders, excluding those with prior mental health disorders.
Care Setting

Key Highlights

  • Include specific psychiatric evaluations and treatments referenced.

Guideline-Based Recommendations

Diagnosis

    Management

    • Implement multidisciplinary management strategies that include psychiatric evaluation and treatment, such as collaboration with psychologists and psychiatrists.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Adults with atopic dermatitis, hidradenitis suppurativa, and psoriasis.

        Psychiatric and psychological interventions are beneficial and necessary for holistic treatment.

        Clinical Best Practices

        • Incorporate mental health assessments into routine dermatologic care by training dermatologists on screening tools.

        Related Resources & Content

        Original Source(s)

        Psychiatric and Psychological Care Utilization Among Patients with Atopic Dermatitis, Hidradenitis Suppurativa, and Psoriasis: Insights from a Propensity-Matched Real-World Cohort Analysis

        • by Marta Szepietowska, Piotr K. Krajewski, Przemyslaw Pacan, Anna Wojas-Pelc, Jacek C. Szepietowski, Andrzej K. Jaworek

        • March 3, 2026

        Related Content

        Correction: Reorganization and functional divergence of the CD4+ memory T cell compartment in hidradenitis suppurativa

        FDA Approves Pediatric Risankizumab

        Approval expands risankizumab use to pediatric plaque psoriasis and psoriatic arthritis and includes a new 55-mg prefilled syringe for weight-based dosing in patients weighing less than 40 kg.

        GLP-1 RAs May Ease Psoriasis, PsA Data Limited

        Published evidence linked liraglutide and semaglutide to improvements in psoriasis severity, inflammatory markers, and metabolic outcomes, while evidence in psoriatic arthritis remained sparse.